InflaRx (IFRX) Short-Term Debt repayments (2019 - 2026)
InflaRx's (IFRX) quarterly Short-Term Debt repayments came in at -$87443.0 in Q1 2026, up 16.95% year-on-year from -$74769.1 in Q1 2025, and down 3.29% quarter-over-quarter from -$84656.2 in Q4 2025.
InflaRx (IFRX) Short-Term Debt repayments (2019 - 2026) Analysis & Trends
InflaRx has disclosed Short-Term Debt repayments across 8 years of filings, most recently posting -$87443.0 for Q1 2026.
- Short-Term Debt repayments for Q1 2026 came in at -$87443.0, up 16.95% year-over-year; the trailing twelve-month figure through Mar 2026 was -$384391.5 (up 11.06% YoY), and the FY2025 annual result was -$416242.2, changed 0.36% from the prior year.
- Short-Term Debt repayments came in at -$87443.0 for Q1 2026 at InflaRx, down from -$84656.2 in the prior quarter.
- In the past five years, Short-Term Debt repayments ranged from a high of -$84656.2 in Q4 2025 to a low of -$115600.7 in Q2 2024.
- The 5-year median for Short-Term Debt repayments is -$100619.4 (2023), against an average of -$99910.2.
- Across the five-year window, Short-Term Debt repayments retreated 16.6% in 2024 and climbed 19.14% in 2025, its largest moves.
- InflaRx's Short-Term Debt repayments stood at -$93187.4 in 2022, then dropped by 9.57% to -$102108.8 in 2023, then dropped by 2.53% to -$104689.2 in 2024, then climbed by 19.14% to -$84656.2 in 2025, then declined by 3.29% to -$87443.0 in 2026.
- The last three Short-Term Debt repayments figures came in at -$87443.0 (Q1 2026), -$84656.2 (Q4 2025), and -$99314.7 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Short-Term Debt repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 102,000.00 |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -482,347.21 |
| 10 | InflaRx | 764.68 Mn | 764.68 Mn | 10,877.40 | -87,442.99 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -87,442.99 |
| Mar 31, 2026 | -87,442.99 |
| Dec 31, 2025 | -84,656.23 |
| Dec 31, 2025 | -84,656.23 |
| Sep 30, 2025 | -99,314.74 |
| Sep 30, 2025 | -99,314.74 |
| Jun 30, 2025 | -112,977.50 |
| Jun 30, 2025 | -112,977.50 |
| Mar 31, 2025 | -105,290.48 |
| Mar 31, 2025 | -105,290.48 |
| Dec 31, 2024 | -104,689.22 |
| Dec 31, 2024 | -104,689.22 |
| Sep 30, 2024 | -106,628.33 |
| Sep 30, 2024 | -106,628.33 |
| Jun 30, 2024 | -115,600.65 |
| Jun 30, 2024 | -115,600.65 |
| Mar 31, 2024 | -93,107.72 |
| Mar 31, 2024 | -93,107.72 |
| Dec 31, 2023 | -102,108.85 |
| Dec 31, 2023 | -102,108.85 |